Via TetraLogic:
MALVERN, Pa., August 19, 2013 – TetraLogic Pharmaceuticals, a biopharmaceutical company
developing novel small molecule SMAC mimetic drugs to treat cancer, today announced the appointment
of a new senior executive leadership team with the goal of accelerating the development of the company
and its lead product candidate birinapant. The new TetraLogic senior executives are J. Kevin Buchi,
President and Chief Executive Officer, Pete A. Meyers, Chief Financial Officer, and Lesley Russell,
MBChB, MRCP, Chief Operating Officer. John M. Gill, the departing President, Chief Executive Officer
and Co-founder of TetraLogic, will continue to serve on the company’s Board of Directors.
“I am pleased to hand over the reins to Kevin who is a highly regarded leader within our industry,” stated
Mr. Gill. “Together with Pete Meyers and Lesley Russell, this team represents the ideal complement to
the existing team at TetraLogic, bringing the expertise and experience we need to maximize the value of
our lead SMAC mimetic drug candidate birinapant, grow the company, and realize the full economic
potential of our commercial opportunities for our shareholders.”
“I am honored to be chosen to lead TetraLogic at this very exciting time for the company,” stated Mr.
Buchi. “With a strong team and clear leadership position in SMAC mimetics, we have a tremendous
opportunity to continue the momentum established for birinapant as a potential treatment for both solid
tumors and hematological malignancies. Having spent most of my career in the biotech industry, I have a
strong sense of the opportunities for success at TetraLogic and look forward to leading the company into
what promises to be an exciting future.”
Read more: http://files.shareholder.com/downloads/AMDA-2C8MW4/2989657472x0x707407/d77fd66f-c0e6-4b0a-9cd9-fd8eb1602e6b/707407.pdf
RSS Feed
